Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432088 | 0.79 | SLC6A2 (0.44) | TAAR1CALM1GBA1SLC6A2SLC6A4 | |
| SCHEMBL2246577 | 0.76 | TAAR1 (0.50) | TAAR1TDP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15710064 | 0.74 | TAAR1 (0.46) | TAAR1MAOB | |
| SCHEMBL22722 | 0.73 | GBA1 (0.42) | TAAR1GBA1LTB4RLTB4R2SLC6A2 | |
| SCHEMBL5269537 | 0.73 | GBA1 (0.42) | TAAR1GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3617768 | 0.73 | MAOB (0.44) | MAOBLTB4RLTB4R2CTRB1 | |
| SCHEMBL30754361 | 0.72 | LTB4R (0.44) | TAAR1GBA1MAOBLTB4RLTB4R2 | |
| SCHEMBL1558896 | 0.72 | LTB4R (0.44) | TAAR1GBA1MAOBLTB4RLTB4R2 | |
| SCHEMBL1100674 | 0.72 | GBA1 (0.37) | TAAR1GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30754350 | 0.72 | LTB4R (0.44) | TAAR1GBA1MAOBLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10649 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227116-A1 | EPH-EPHRIN TETRAMERIZATION INHIBITORS THAT TARGET A PREVIOUSLY UNKNOWN AND VERY HIGH-AFFINITY CHELATOR-TYPE INTERMOLECULAR PROTEIN-PROTEIN INTERACTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | claimed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| US-20230014962-A1 | Quinoline compound and use thereof | SKYRUN PHARMA CO LTD (CN) | 2023-01-19 | — | — | US | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| EP-4083031-A1 | QUINOLINE COMPOUND AND APPLICATION THEREOF | Skyrun Pharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | claimed |
| US-20210379052-A1 | QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-12-09 | — | — | US | claimed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | claimed |
| WO-2000042019-A1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | claimed |
| US-6090797-A | ADJUSTMENT OF GLUCOSE METABOLISM; HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2000-07-18 | — | — | US | claimed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0537517-B1 | Method for the preparation of 2,2-difluorobenzo(1,3)dioxolecarbaldehydes and intermediates | BAYER AG (DE) | 1997-01-22 | — | — | EP | claimed |
| EP-0537518-B1 | Derivatives of 2,2-dihalobenzo(1,3)dioxoles substituted in the 4-position, methods for their preparation and their use | BAYER AG (DE) | 1996-04-17 | — | — | EP | claimed |
| US-5420308-A | 2,2-difluorobenzo (1,3)-dioxole-carbaldehydes and new intermediate products | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | claimed |
| EP-0537518-A1 | Derivatives of 2,2-dihalobenzo(1,3)dioxoles substituted in the 4-position, methods for their preparation and their use | BAYER AG (DE) | 1993-04-21 | — | — | EP | claimed |